<DOC>
	<DOCNO>NCT01912391</DOCNO>
	<brief_summary>Selegiline superior placebo improve psychological physical functioning patient Borderline Personality Disorder .</brief_summary>
	<brief_title>Clinical Research Study Evaluate Selegiline Treatment Borderline Personality Disorder</brief_title>
	<detailed_description>Borderline Personality Disorder ( BPD ) chronic disorder occur 2-3 % population . BPD accompany high level co-existing psychiatric physical disorder . One key predictor persistent recur major depressive disorder . Since BPD closely link mood disorder depression particular , use antidepressant medication treat disorder logical . However , date , FDA approve treatment BPD . The American Psychiatric Association 's Treatment Guidelines Borderline Personality Disorder recommend antidepressant primary treatment disorder . Earlier trial use antidepressant increase certain brain chemical , , serotonin noradrenalin show efficacy control mood swing illness many people . These study also document efficacy control physical disorder , include headache , migraine , irritable bowel , neurodermatitis ( skin rash ) , fibromyalgia , premenstrual syndrome , tempomandibular joint dysfunction ( TMJ ) . group antidepressant know monoamine oxidase inhibitor ( MAOIs ) also show effective BPD patient . The oral form medication accompany dietary restriction , potential drug interaction , blood pressure change weight gain . Selegiline , MAOI antidepressant , put skin patch delivery system ( transdermal ) reduce side-effect profile . Trials without placebo control show many individual BPD benefit selegiline skin patch . This trial look individual selegiline placebo make sure selegiline effective treating BPD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<criteria>Subject primary diagnosis Borderline Personality Disorder ( BPD ) . Subject Symptomatology BPD least 1 year . Subject understand study procedure voluntarily agree participate . Subject able read , understand complete questionnaire . Subject agrees use ( 2 ) acceptable form contraception throughout study . Patient must screen SCL 90R score &gt; 120 ( range 0360 ) . Subject pregnant breast feeding . Subject unlikely adhere study procedure restriction . Patient fail treatment due lack efficacy monoamine oxidase inhibitor ( MAOI ) medication . Patient anticipate need surgery study . Patient another predominant personality disorder BPD . Subject active history substance abuse dependence , e.g. , Positive Drug screen Subject health issue could interfere study interpretation . Subject report recent suicide attempt homicide attempt past 3 month . Subject must substance abuse dependence clean ( 1 ) year . Subject history primary malignancy &lt; 5 yr . Subject medical condition ( ) exclude , per Protocol , unstable . Subject abnormal screen laboratory value , per Protocol , clinically significant , unexplained laboratory abnormality . Subject currently participate participate study within 30 day . Patient donate blood product phlebotomy &gt; 300 ml within 8 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Headaches</keyword>
	<keyword>Migraines</keyword>
	<keyword>Irritable Bowel Syndrome IBS</keyword>
	<keyword>Neurodermatitis</keyword>
	<keyword>Fibromyalgia</keyword>
	<keyword>Premenstrual Syndrome PMS</keyword>
	<keyword>Temporomandibular Joint Dysfunction TMJ</keyword>
</DOC>